RET-Positive Metastatic NSCLC

 

RET-Positive Metastatic NSCLC
23:53

Priyanka Iyer

Biomarkers in Thyroid Cancer: Endocrinologist's Perspective

  • 476 views
  • September 12, 2022
  • 1
14:05

Yale School of Medicine

Molecular Markers in Thyroid Cancer from the Endocrinologist's Perspective

FEATURING Elizabeth Holt
  • 1,255 views
  • August 31, 2022
  • 6
14:11

Lorenzo Belluomini

Selpercatinib in RET Fusion-Positive mNSCLC: Achievements and Gray Areas

  • 1,096 views
  • August 8, 2022
  • 8
01:01

Lorenzo Belluomini

Lecture Summary - Selpercatinib in RET Fusion-Positive mNSCLC: Achievements and Gray Areas

  • 750 views
  • August 8, 2022
  • 3
19:19

Nicola Normanno

Rebiopsy and cfDNA in a Complex and Changing NSCLC Landscape

  • 84 views
  • May 27, 2022
  • 1
15:19

GRACE

The Role of Chemotherapy in Driver Positive NSCLC

FEATURING Jared Weiss
  • 37 views
  • June 3, 2022
  • 1
13:32

CancerGRACE

Targeted Therapies in Oligo-Metastatic NSCLC

FEATURING Ticiana Leal
  • 35 views
  • June 3, 2022
05:02

ASCO 2022 Conference Coverage

ASCO 2022 on IO and Chemo-IO for NSCLC With Novel Actionable Oncogenic Driver Alterations

FEATURING Laura Mazzeo, Mario Occhipinti
  • 175 views
  • June 21, 2022
  • 1
07:37

ASCO 2022 Conference Coverage

ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo in 1L mNSCLC: AE Management in POSEIDON Trial

FEATURING Byoung Chul Cho
  • 54 views
  • June 23, 2022
01:28

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo in 1L mNSCLC: AE Management in POSEIDON Trial

FEATURING Byoung Chul Cho
  • 8 views
  • June 23, 2022
06:45

WCLC 2022 Conference Coverage

WCLC 2022 on the Phase 3 SANOVO Study: Savolitinib or Placebo in Combination With Osimertinib in EGFRm and MET Overexpressed NSCLC

FEATURING Qing Zhou
  • 156 views
  • August 18, 2022
07:18

WCLC 2022 Conference Coverage

WCLC 2022 on the NADIM II Trial: Pre-Treatment ctDNA Levels Significantly Predict OS & PFS in Locally Advanced & Potentially Resectable NSCLC

FEATURING Atocha Romero
  • 84 views
  • August 18, 2022
  • 1
04:11

WCLC 2022 Conference Coverage

WCLC 2022 on 1L Chemotherapy vs. Chemoimmunotherapy in Stage IV LCNEC of the Lung

FEATURING Lingbin Meng
  • 77 views
  • August 18, 2022
  • 1
35

WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on 1L Chemotherapy vs. Chemoimmunotherapy in Stage IV LCNEC of the Lung

FEATURING Lingbin Meng
  • 1 view
  • August 18, 2022
09:13

WCLC 2022 Conference Coverage

WCLC 2022 on KEYNOTE B36: A Pilot Study of 1L Tumor Treating Fields (150 kHz) + Pembro for Advanced/Metastatic NSCLC

FEATURING Rupesh Kotecha
  • 55 views
  • August 23, 2022
  • 2
01:22

WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on KEYNOTE B36: A Pilot Study of 1L Tumor Treating Fields (150 kHz) + Pembro for Advanced/Metastatic NSCLC

FEATURING Rupesh Kotecha
  • 6 views
  • August 23, 2022
15:13

Feredun Azari

Intraoperative Molecular Imaging Guided Resection of CEACAM5+ Lung Tumors: First In-Human SGM-101 Lung Cancer Surgical Trial

  • 15 views
  • August 29, 2022
01:13

Feredun Azari

Lecture Summary - Intraoperative Molecular Imaging Guided Resection of CEACAM5+ Lung Tumors: First In-Human SGM-101 Lung Cancer Surgical Trial

  • 1 view
  • August 29, 2022
12:35

WCLC 2022 Conference Coverage

WCLC 2022 on Socio-Economic Inequalities in NSCLC Treatment During the Era of Tumor Biomarker Guided Therapy: A Population-Based Study

FEATURING Ruth Norris
  • 32 views
  • August 29, 2022
56

WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on Socio-Economic Inequalities in NSCLC Treatment During the Era of Tumor Biomarker Guided Therapy: A Population-Based Study

FEATURING Ruth Norris
  • 76 views
  • August 29, 2022
  • 1
05:34

WCLC 2022 Conference Coverage

WCLC 2022 on the Phase II DOLPHIN Study: Durvalumab + Concurrent RT in Unresectable Locally Advanced NSCLC

FEATURING Motoko Tachihara
  • 63 views
  • August 29, 2022
08:26

ESMO 2022 Conference Coverage

ESMO 2022 on the Results of the Randomized DICIPLE Phase 3 Trial: Nivo + Ipi 6-Month Treatment vs. Continuation in Advanced NSCLC

FEATURING Gerard Zalcman
  • 1,085 views
  • September 15, 2022
  • 2
03:24

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Results of the Randomized DICIPLE Phase 3 Trial: Nivo + Ipi 6-Month Treatment vs. Continuation in Advanced NSCLC

FEATURING Gerard Zalcman
  • 6 views
  • September 15, 2022